Neuroscience

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market, Trends, Analysis, Opportunities, Share and Forecast 2019-2025 – Digits N Markets News

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market to reach USD 5.1 billion by 2025. The increasing automation of high-throughput screening and the availability of robust data management software tools, which enable researchers to develop systemic and process-oriented approaches toward neuroscience antibodies and assays techniques are some of the factors contributing to the growth of this segment.

Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market valued approximately USD 2.1 billion in 2016 is anticipated to grow with a healthy growth rate of more than 10.3% over the forecast period 2017-2025

To request a sample copy or view summary of this report, click the link below: http://digitsnmarkets.com/sample/5594-global-neuroscience-antibodies-and-assays-market

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product

By Technology

By End-User

Some of the key manufacturers involved in the market are. Thermo Fisher Scientific, Abcam, Bio-Rad, Merck KGAA, Cell Signaling Technology, Genscript, Rockland Immunochemicals. Bio Legend, Santa Cruz Biotechnology, Tecan, F. Hoffmann-La Roche, Siemens. Acquisitions and effective mergers are some of the strategies adopted by the key manufacturers. New product launches and continuous technological innovations are the key strategies adopted by the major players.

About Digits N Markets:

Digits N Markets has a vast repository of latest market research reports on trending topics, niche company profiles, market size and other relevant data released by renowned publishers. We have access to the database related to niche markets and trending topics in various industries. We also update the data regularly to provide recent statistics to the client. Recent data and reports will be featured on our websites and clients will be able to access the same. Our clients will be able to benefit from qualitative & quantitative insights in the report which will support them in taking concrete business decisions.

Contact Us :Digits N Markets 410 E Santa Clara Street, Unit #762San Jose, CA 95113Phone :+1 408-622-0123Email: sales@digitsnmarkets.comWebsite:- http://www.digitsnmarkets.com

Read the original here:
Global NEUROSCIENCE ANTIBODIES AND ASSAYS Market, Trends, Analysis, Opportunities, Share and Forecast 2019-2025 - Digits N Markets News

Neuroscience

Neuroscience Antibodies & Assays Market 2020 : Global Analysis On Key Companies Like Roche Ltd, Thermo Fisher Scientific And Industry Forecast By…

Neuroscience antibodies & assays market is anticipated to grow with a significant rate in the coming years, owing to the increasing incidence of neurological disorders, growing pharmaceutical & biotechnology industries and increasing investments in neuroscience research. On the other hand, increasing research & development activities are projected to offer novel growth opportunities for the players operating in the neuroscience antibodies & assays market, in the coming years

Neuroscience involves the study of nervous system, where the research is completely relies on assays and antibodies. These antibodies and assays are specific that helps to identify and examine reactions on the cellular, biochemical and molecular level. Antibody-based approaches are used for the localization, isolation and characterization of targeted proteins that majorly used in the cellular and molecular neuroscience. On the other hand, the use of assays provide an efficient, valuable solution for determination of critical targets that are involved in synaptic signaling, neural development and neurodegeneration.

Get Sample PDF of thisReport@https://www.theinsightpartners.com/sample/TIPBT00002234/

Global Neuroscience Antibodies & Assays Market Analysis to 2027 is a specialized and in-depth study with a special focus on the global medical device market trend analysis. The report aims to provide an overview of neuroscience antibodies & assays market with detailed market segmentation by product, technology, application, end user and geography. The global neuroscience antibodies & assays market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading neuroscience antibodies & assays market players and offers key trends and opportunities in the market.

Below mentioned is the list of few companies engaged in the neuroscience antibodies & assays market:-

As, The report also includes the profiles of key neuroscience antibodies & assays market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

Key developments in the neuroscience antibodies & assays market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from neuroscience antibodies & assays market are anticipated to lucrative growth opportunities in the future with the rising demand for neuroscience antibodies & assays in the global market.

The global neuroscience antibodies & assays market is segmented:-on the basis of product, technology, application and end user. Based on product, the market is segmented as consumables and instruments. On the basis of technology, the global neuroscience antibodies & assays market is segmented into molecular diagnostics, clinical chemistry, immunoassays/immunochemistry and others. Based on application, the market is segmented as in vitro diagnostics, research and drug discovery. Based on end user, the market is segmented as hospitals & diagnostics centers, academic & research institutes and pharmaceutical & biotechnology companies.

e report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global neuroscience antibodies & assays market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The neuroscience antibodies & assays market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting neuroscience antibodies & assays market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the neuroscience antibodies & assays market in these regions.

Buy thisReport@https://www.theinsightpartners.com/buy/TIPBT00002234/

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services.

We are committed to providing highest quality research and consulting services to our customers. We help our clients understand key market trends, identify opportunities, and make informed decisions by providing market research solutions at an affordable cost.

Contact us:

The Insight partners,

Phone: +1-646-491-9876

Email:sales@theinsightpartners.com

Read the rest here:
Neuroscience Antibodies & Assays Market 2020 : Global Analysis On Key Companies Like Roche Ltd, Thermo Fisher Scientific And Industry Forecast By...

Neuroscience

Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning – Business Wire

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimers disease (AD) and other neurodegenerative disorders, announced today that Peter N. Laivins, MBA, has been appointed Head of Commercial Strategy and Planning. Mr. Laivins brings more than 20 years of leadership in the biopharmaceutical industry, with broad expertise in business strategy and commercialization for Alzheimers therapies, including his experience at Pfizer launching ARICEPT for symptomatic treatment for AD and at Elan Biopharmaceuticals leading commercial strategy for bapineuzumab as an anti-amyloid immunotherapy for AD.

Peter brings unparalleled depth of business and commercial expertise to Alzheon, with a unique track record of shaping the Alzheimers commercial landscape and a career-long passion to fight this debilitating disease, said Martin Tolar, MD, PhD, Founder, President and Chief Executive Officer of Alzheon. Peters skills will be invaluable as we move our lead drug ALZ-801 into Phase3 trials and prepare for future commercialization of potentially the first oral and well tolerated disease-modifying treatment for millions of Alzheimers patients and their families.

Most recently, Mr. Laivins was the Senior Vice President of Strategic Development Program Leadership at Tesaro, Inc., with oversight of five development teams, portfolio management and competitive intelligence. Previously, at Merrimack Pharmaceuticals, he served as Senior Vice President and Head of Late Stage Development, where he led the successful clinical development, NDA submission and FDA approval of Onyvide the first new therapy for pancreatic cancer in two decades. Mr. Laivins career in neuroscience drug development includes his role as Vice President of Strategic Brand Management for Elan Biopharmaceuticals, with responsibility for the Alzheimers portfolio, including bapineuzumab, and the multiple sclerosis portfolio, including TYSABRI. At Pfizer, Mr. Laivins held positions of increasing responsibility, including the Global Team Leader in Neuroscience, leading the launch of Aricept which achieved peak sales exceeding $3 billion. Beyond neuroscience, he also served as Group Leader for US Oncology Marketing at Pfizer. Mr. Laivins is a graduate of McGill University with a Bachelor of Science in microbiology and immunology and Master of Business Administration.

Im excited to join the team at Alzheon at this important juncture in Alzheimers drug development. Last year we saw convincing clinical validation of anti-amyloid therapy, which confirmed that targeting amyloid toxicity can slow disease progression and provide clinical improvement in patients, said Mr. Laivins. We believe ALZ-801 could be transformative as the first oral disease modifying treatment for Alzheimers and provide an important advance for patients and their families.

About ALZ-801

Alzheons lead product candidate, ALZ-801, an oral anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, has shown promising results in analyses of clinical data1,2 and a novel therapeutic mechanism of action.3 ALZ-801 has received Fast Track designation from the U.S. Food and Drug Administration. The clinical data for ALZ-8014 and its active agent, tramiprosate, suggest long-term clinical efficacy in AD patients with the apolipoprotein E4 (APOE4) genotype and a favorable safety profile.1,2 ALZ-801 acts through a novel enveloping molecular mechanism of action blocking the formation of toxic amyloid oligomers3 associated with the development and progression of AD.6 The cognitive improvements observed in AD patients in the tramiprosate Phase 3 studies may be attributed, in part, to the therapeutic anti-oligomer action of 3-sulfopropanoic acid (3-SPA), an endogenous substance in the human brain, discovered by Alzheon scientists, that inhibits the formation of neurotoxic beta amyloid oligomers.5 3-SPA is the primary metabolite of ALZ-801 in humans and its discovery elucidates the beneficial pharmaceutical attributes of ALZ-801, including a favorable safety profile, selectivity against beta amyloid oligomers, and excellent brain penetration. ALZ-801 increases levels of 3-SPA in the brain and augments the bodys natural mechanism for blocking the formation of toxic amyloid oligomers.5 The initial Phase 3 program for ALZ-801 will focus on patients with the homozygous APOE4/4 genotype at the Early stage of AD, with the potential for future expansion to additional Alzheimers populations.6

About Alzheon

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimers clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of beta amyloid aggregation and neurotoxicity hallmarks of Alzheimers disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimers patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.

Alzheon Publications1Abushakra et al. Journal of Prevention of Alzheimers Disease, 20162Abushakra et al. Journal of Prevention of Alzheimers Disease, 20173Kocis et al. CNS Drugs, 20174Hey et al. Clinical Pharmacokinetics, 20185Hey et al. CNS Drugs, 20186Tolar et al. Alzheimers & Dementia, 2019

Original post:
Alzheon Announces Appointment of Peter N. Laivins as Head of Commercial Strategy and Planning - Business Wire

Neuroscience

The 13 Universal Emotions Evoked by Music – Technology Networks

The Star-Spangled Banner stirs pride. Ed Sheerans The Shape of You sparks joy. And ooh l l! best sums up the seductive power of George Michaels Careless Whisper.

UC Berkeley scientists have surveyed more than 2,500 people in the United States and China about their emotional responses to these and thousands of other songs from genres including rock, folk, jazz, classical, marching band, experimental and heavy metal.

The upshot? The subjective experience of music across cultures can be mapped within at least 13 overarching feelings: Amusement, joy, eroticism, beauty, relaxation, sadness, dreaminess, triumph, anxiety, scariness, annoyance, defiance, and feeling pumped up.

Imagine organizing a massively eclectic music library by emotion and capturing the combination of feelings associated with each track. Thats essentially what our study has done, said study lead author Alan Cowen, a UC Berkeley doctoral student in neuroscience.

We have rigorously documented the largest array of emotions that are universally felt through the language of music, said study senior author Dacher Keltner, a UC Berkeley professor of psychology.

Cowen and fellow researchers have translated the data into an interactive audio map where visitors can move their cursors to listen to any of thousands of music snippets to find out, among other things, if their emotional reactions match how people from different cultures respond to the music.

Potential applications for these research findings range from informing psychological and psychiatric therapies designed to evoke certain feelings to helping music streaming services like Spotify adjust their algorithms to satisfy their customers audio cravings or set the mood.

While both U.S. and Chinese study participants identified similar emotions such as feeling fear when hearing the Jaws movie score they differed on whether those emotions made them feel good or bad.

People from different cultures can agree that a song is angry but can differ on whether that feeling is positive or negative, said Cowen, noting that positive and negative values, known in psychology parlance as valence, are more culture-specific.

Across cultures, study participants mostly agreed on general emotional characterizations of musical sounds, such as anger, joy and annoyance. But their opinions varied on the level of arousal, which refers in the study to the degree of calmness or stimulation evoked by a piece of music.

How they conducted the study

For the study, more than 2,500 people in the United States and China were recruited via Amazon Mechanical Turks crowdsourcing platform.

First, volunteers scanned thousands of videos on YouTube for music evoking a variety of emotions. From those, the researchers built a collection of audio clips to use in their experiments.

Next, nearly 2,000 study participants in the United States and China each rated some 40 music samples based on 28 different categories of emotion, as well as on a scale of positivity and negativity, and for levels of arousal.

Using statistical analyses, the researchers arrived at 13 overall categories of experience that were preserved across cultures and found to correspond to specific feelings, such as depressing or dreamy.

To ensure the accuracy of these findings in a second experiment, nearly 1,000 people from the United States and China rated over 300 additional Western and traditional Chinese music samples that were specifically intended to evoke variations in valence and arousal. Their responses validated the 13 categories.

Vivaldis Four Seasons made people feel energized. The Clashs Rock the Casbah pumped them up. Al Greens Lets Stay Together evoked sensuality and Israel (Iz) Kamakawiwooles Somewhere over the Rainbow elicited joy.

Meanwhile, heavy metal was widely viewed as defiant and, just as its composer intended, the shower scene score from the movie Psycho triggered fear.

Researchers acknowledge that some of these associations may be based on the context in which the study participants had previously heard a certain piece of music, such as in a movie or YouTube video. But this is less likely the case with traditional Chinese music, with which the findings were validated.

Cowen and Keltner previously conducted a study in which they identified 27 emotions in response to visually evocative YouTube video clips. For Cowen, who comes from a family of musicians, studying the emotional effects of music seemed like the next logical step.

Music is a universal language, but we dont always pay enough attention to what its saying and how its being understood, Cowen said. We wanted to take an important first step toward solving the mystery of how music can evoke so many nuanced emotions.

Reference

Cowen et al. (2020) What music makes us feel: At least 13 dimensions organize subjective experiences associated with music across different cultures. PNAS. DOI: https://doi.org/10.1073/pnas.1910704117

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
The 13 Universal Emotions Evoked by Music - Technology Networks

Neuroscience

VoxNeuro Announces Research Project With St. Joseph’s Healthcare Hamilton – Business Wire

HAMILTON, Ontario--(BUSINESS WIRE)--At the close of 2019, VoxNeuro joined a pilot study conducted by the Womens Health Concerns Clinic & Mood Disorders Program at St. Josephs Healthcare Hamilton. The study is led by Dr. Benicio Frey and Dr. Flavio Kapczinski, and has been designed to identify biomarkers of bipolar disorder.

Dr. Frey, the studys Principal Investigator, is the Academic Head of the Mood Disorders Program, and is the Medical Director of the Womens Health Concerns Clinic at St. Joseph's Healthcare. He also holds the position of Associate Professor at the Department of Psychiatry and Behavioural Neurosciences at McMaster University. Specializing in psychiatry, biochemistry and brain imaging in bipolar disorder, Dr. Frey has more than 150 articles published in peer-reviewed journals.

Dr. Kapczinski, Psychiatrist at St. Josephs Healthcare Hamilton, professor and Director of the Neuroscience Graduate Program at McMaster University, is a leading author in the area of mood disorders and has published over 430 peer-reviewed articles (over 22,000 citations). Dr. Kapczinski and colleagues helped to develop the concepts of neuroprogression and staging in bipolar disorder, published in 2009. This current study intends to add objective details to Dr. Kapczinskis staging model by assessing whether the brains connectivity alterations are associated with illness progression in bipolar disorder.

Dr. Kapczinski was an early supporter of VoxNeuros work, founded on the lifetime research of Dr. John F. Connolly, a colleague of Dr. Kapczinski at McMaster University and VoxNeuros Chief Science Officer. In an interview in the fall of 2017, Dr. Kapczinski spoke to the potential of VoxNeuros Cognitive Health Assessments and the impact they will have on both brain injuries and mood disorders, If someone is having depressive symptoms but then we think the origin is actually repeated brain injuries, having a tool that can confirm that can put us on the right trackHaving an objective measurement related to the brain function of people who have suffered traumatic brain injuries is enormous, clinically.

For this project, the teams are collaborating on the assessments application to mood disorders, specifically bipolar. The current classifications of psychiatric diagnoses are based purely on behavioural observation and self-report, and lack of substantial biological validation. This contrasts sharply with the rest of medicine where diagnosis and treatment are routinely aided by biological tests that are based on validated biomarkers. Biological markers, or biomarkers, are quantitative measurements that provide information about biological processes, a disease state, or about response to treatment (FDAs Biomarkers Research Group definition). The objective of the study is to create a biological bank of potential biomarkers to investigate etiology, prognosis, and/or treatment response in individuals with bipolar disorder.

VoxNeuros Cognitive Health Assessments are being used alongside blood tests and various behavioural and clinical assessments to identify the most effective tools to accurately predict onset, diagnose, inform prognoses and track treatment responses for bipolar disorder. Specifically, in addition to the objective reports provided by VoxNeuros Cognitive Health Assessments, the EEG data is being used to investigate functional connectivity patterns as a potential biomarker for bipolar disorder. A recent review showed that abnormal fronto-cortical connectivity may be involved in bipolar disorder across mood states. These connectivity disturbances possibly contribute to emotional dysregulation, and cognitive impairments in bipolar disorder.

If the pilot study results support the hypothesis, a follow-on multi-year longitudinal study will be pursued to widen the data, track participants throughout diagnoses & treatment, and assess the accuracy of prognoses. This is one of VoxNeuros first examples of being integrated into a clinical study to provide objective measures to guide the examination of researchers hypotheses.

Were looking forward to working closely with St. Josephs Healthcare and St. Joes Research Institute on this project. Its a perfect example of the strong opportunities that exist between VoxNeuro, other innovative healthcare startups being built in this region, and the industry leading healthcare teams right here in our own backyard. Spinning our technology out of McMaster University, were extremely fortunate to be headquartered in Hamilton Canadas leading health sciences research cluster, says Kimberly Elliott, COO of VoxNeuro.

Read the original:
VoxNeuro Announces Research Project With St. Joseph's Healthcare Hamilton - Business Wire

Neuroscience

BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia -…

Foundational study with plans to address multiple types of agitation associated with dementia

Expands the potential therapeutic use of BXCL501 beyond neuropsychiatric disorders

Topline results expected in mid-2020

NEW HAVEN, Conn., Jan. 07, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the first patient has been enrolled in a Phase 1b/2 study of BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), for the acute treatment of agitation in patients with dementia.

We are excited to advance the clinical development of BXCL501 in agitation associated with dementia, a third potential indication for our lead product candidate, commented Robert Risinger, M.D., Vice President, Clinical Development of BTAI. With no approved treatments, there is a significant need for better treatment options for the 6 million patients in the U.S. with dementia, many of whom will experience agitation during the course of their disease. We believe our candidate, BXCL501, with its unique mechanism and convenient oral dosing, has the potential to rapidly reduce agitation associated with dementia without excessive sedation or other undesired side effects. This study builds upon the foundation for a broad BXCL501 program in dementia, including the treatment of chronic agitation and the prevention of agitation using a wearable device in combination with BXCL501.

The multicenter, randomized, double-blind, placebo-controlled, ascending dose Phase 1b/2 study is designed to evaluate the efficacy, pharmacokinetics, safety and tolerability of BXCL501 in adults 65 years and older who exhibit acute agitation associated with all forms of dementia, including Alzheimer's disease. The dementia program expands on the Phase 1b study performed with BXCL501 in 135 patients with agitation associated with schizophrenia, and also builds on the positive results observed in reducing agitation with intravenous Dex in Alzheimers disease patients. This is an adaptive design and is expected to assess multiple dose cohorts of BXCL501 or matching placebos. Following the completion of each dose cohort, a safety and tolerability review is expected to be performed to determine the next tested dose. The study is designed to assess agitation as measured by the Pittsburgh Agitation Scale, a validated clinical instrument, as well as improvement in the modified Cohen Mansfield Agitation Inventory and Positive and Negative Syndrome Scale, Excitatory Component (PEC).

About BXCL501

BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia.

About Agitation Associated with DementiaDementia is a neurocognitive condition caused by damage to brain cells that leads to a decline in cognitive abilities and independent function. It affects approximately 6 million individuals in the United States, with Alzheimers disease accounting for 60-70% of these cases. During the course of the disease, patients with dementia often suffer from psychological and behavioral symptoms, such as agitation, which has been reported in up to 70% of patients. Agitation associated with dementia can negatively affect both the patient and caregivers quality of life. Caregiver burden can contribute significantly to burnout, which can result in premature institutionalization of the patient. Treating agitation associated with dementia has been a challenge for providers and current standards of care often have a slow onset of action and/or cause excessive sedation. There are currently no FDA-approved therapies for the treatment of dementia-related agitation, and off-label therapies have black box warnings associated with their use.

About BioXcel Therapeutics, Inc.BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.

Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the timing and data from clinical development initiatives and trials for BXCL501. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

Source: BioXcel Therapeutics, Inc.

More:
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 Study of BXCL501 for Acute Treatment of Agitation Associated with Dementia -...

Neuroscience

Sight loss research needs urgent investment – The Guardian

As leading ophthalmologists and researchers we are joining the eye research charity Fight for Sight to call for urgent action on blindness in 2020 to address the research funding gap.

We know that serious sight loss doesnt discriminate it can affect anyone at any time and it is on the increase. Science can already do so much and with the advent of new gene therapies and stem cell treatments we are so close to outcomes that were not possible a decade ago. Yet so much more needs to be done to develop new universal treatments.

The main barrier is the lack of research funding. It is unacceptable that in 2020 only 1% of UK grant funding goes to eye research, even though more than 20% of people will be affected by serious sight loss in their lifetime. Blindness can have a huge impact on peoples mental health and ability to work, increasing costs on health systems and infrastructure.

In 2019 the WHO and UN general assembly both outlined that globally more investment is needed into sight loss and research. We are calling for the new government and its partners to agree a national plan on sight loss and a research agenda that will help to ensure that eye research gets the funding it badly needs. Please join us at fightforsight.org.uk and let 2020 be the year that we accelerate progress in beating blindness.

Prof Chris Hammond Frost chair of ophthalmology, Kings College London, Prof Alan Stitt Dean of innovation and impact, Queens University Belfast, Prof Alastair Denniston Consultant ophthalmologist, Birmingham University, Prof Alison Hardcastle Professor of molecular genetics, UCL Institute of Ophthalmology, Prof Lynda Erskine Chair in developmental neurobiology, Aberdeen University, Prof Jeremy Guggenheim Director of research, Cardiff University, Prof David Steel Consultant ophthalmologist, Newcastle University, Prof Chris Inglehearn Professor of molecular ophthalmology and neuroscience, Leeds University, Prof Timothy Jackson Consultant ophthalmic surgeon, Kings College London, Prof Rachael Pearson Professor of developmental neuroscience, UCL Institute of Ophthalmology, Prof Jessica Teeling Professor of Experimental Neuroimmunology, University of Southampton, Prof Colin Willoughby Professor of ophthalmology, Ulster University

Join the debate email guardian.letters@theguardian.com

Read more Guardian letters click here to visit gu.com/letters

Do you have a photo youd like to share with Guardian readers? Click here to upload it and well publish the best submissions in the letters spread of our print edition

Excerpt from:
Sight loss research needs urgent investment - The Guardian

Cell Biology

Discovery of cellular ‘hands’ could have implications in the fields of cell, developmental biology – News-Medical.net

The protein, called syndecan-4, combines with fellow cell membrane proteins, called integrins, to form protruding 'hands' that sense the environment outside the cell.

Both proteins sit in the cell membrane, with one end pointing inside the cell and the other outside. They are therefore in a prime position to sense conditions outside the cell and convert signals to biochemical messages that change conditions inside the cell. In doing so, they're able to drive some of the cellular processes behind cancer and other diseases.

The early-stage research, conducted by a team at Imperial College London, Queen Mary University of London, and Tampere University in Finland, could present a new research pathway and drug target for certain cancer types.

Lead researcher Dr Armando del Ro Hernndez, of Imperial's Department of Bioengineering, said:

Our findings could have immediate implications in the fields of cell and developmental biology, and lead to developments in several diseases including cancer and fibrosis."

The paper is published today in Nature Materials.

Syndecan-4 exists in nearly every human cell and is already known for its role in cardiovascular disease. However its potential roles in cancer biology and drug development have thus far been overlooked.

To study syndecan-4 the research team, led by Dr del Ro Hernndez, used biophysical, cell biology, and computational techniques.

The team found that activating these cellular 'hands' triggers a pathway with key roles in disease development, involving a cellular protein called the yes-associated protein (YAP).

YAP triggers some of the typical hallmarks of cancer. It reduces cells' ability to program their own death, in a process called apoptosis. Cells initiate apoptosis when they age or malfunction, so halting apoptosis allows diseased, even cancerous, cells to spread. YAP also controls the development of blood vessels - a hallmark of cancer as tumor growth requires extra blood flow.

They also found that syndecan-4 helps cells respond to movements outside themselves, by creating tension in the cytoskeleton - the 'scaffolding' within cells. This makes cells stiffen, which activates an enzyme called PI3K that regulates additional hallmarks of cancer.

It does this by converting the movements outside the cell into biochemical signals which, the researchers found, 'tune' the way the cells respond to tension and movement.

Dr del Ro Hernndez said: "The way cells interact with their environment could inform how we engineer tissues and mimic human organs for drug design. Syndecan-4 could now play a fundamental part in this endeavor."

Co-lead author Dr Stephen Thorpe of Queen Mary University of London said:

As syndecan-4 is expressed on almost all of our cells, the mechanisms we've uncovered could be targeted to alter any number of diseases and biological processes."

Professor Vesa Hytnen of Tampere University said: "Better understanding of cellular mechanosensing opens possibilities to develop treatments for conditions like cancer and fibrosis."

Next, the research team will further investigate syndecan-4's links to specific diseases like pancreatic cancer.

Dr del Ro Hernandez said:

Our next approach will involve syndecan-4 as a key contributor in disease. We hope this will lead to new insights into disease mechanisms."

Read more:
Discovery of cellular 'hands' could have implications in the fields of cell, developmental biology - News-Medical.net

Cell Biology

Fitzpatrick elected to microscopy society governing council – Washington University School of Medicine in St. Louis

Visit the News Hub

Noted for his expertise in cellular imaging, 3D microscopy

Fitzpatrick

James Fitzpatrick, PhD, a professor of neuroscience and of cell biology and physiology at Washington University School of Medicine in St. Louis, has been elected biological sciences director of the Microscopy Society of America. He will serve a three-year term on the societys governing council beginning in 2020.

An expert in biological imaging, Fitzpatrick is the director of the Washington University Center for Cellular Imaging. The center boasts 16 state-of-the-art light, X-ray and electron microscopes including a 300kV Titan Krios cryo-electron microscope and provides imaging expertise and support to researchers at the university and elsewhere.

Fitzpatricks research is focused on developing ways to correlate microscopy using charged particles such as electrons or ions with light microscopy of the same sample. By combining the advantages of charged-particle microscopy methods which generate finely detailed grayscale images at nanoscale resolution and light microscopy which uses color-coded labels to flag molecules or internal cellular structures of interest Fitzpatrick aims to advance our understanding of biological processes in human health and disease. He also is working to use artificial intelligence methods to develop new tools to visualize and manipulate image data obtained from different techniques.

The Microscopy Society of America is dedicated to the promotion and advancement of techniques and applications of microscopy and microanalysis in relevant scientific disciplines. Fitzpatrick plans to use his position on the societys governing council to increase trainee engagement with the society, cultivate mentorship opportunities for early-career scientists and advocate for increased diversity in the community.

Originally posted here:
Fitzpatrick elected to microscopy society governing council - Washington University School of Medicine in St. Louis

Cell Biology

Vapers Reported Adverse Health Effects Online for Years: Study – The Scientist

An analysis of language on an electronic cigarette users online discussion forum shows vapers reported adverse health effects online for at least seven years, long before vaping-associated pulmonary illness, or VAPI, was recognized by the medical community last summer, researchers reported January 3 in the Journal of Medical Internet Research.

The sudden uptick in symptoms and conditions related to VAPI comes at least 10 years after e-cigarette products gained widespread popularity in the United States, including the rise in popularity of JUUL and marijuana vape products, Prue Talbot, a professor of cell biology at the University of California, Riverside, who led the research, says in a media release. Our data, which shows many of the symptoms characterizing the current patients have been reported online for at least seven years, suggests cases similar to those in the current VAPI epidemic have existed previously and been unreported or simply not linked to vaping.

To conduct the study, Talbot and her team collected information from an e-cigarette forum posted between January 2008 and July 2015 and used a web crawler to analyze the language to evaluate the health effects of vaping. Of the 41,000 posts analyzed, 17 percent mentioned positive health effects, 38 percent were neutral, and 45 percent mentioned negative health effects. Although positive symptoms were not frequently reported in the forum, some individuals did mention reduced tiredness, insomnia, and wheezing, while the negative health effects included headache, throat pain, coughing, itching, and uneasiness, similar to some of the symptoms listed for VAPI.

Our data underscore the idea that e-cigarette use is not free of adverse health effects and suggest that the epidemic we are seeing now will continue to grow given the many reports in the forum of symptoms characteristic of VAPI, My Hua, a graduate student in Talbots lab, says in the release. It is important that vigilant reporting of cases, tracking symptoms, and engaging in research on the health effects related to e-cigarette use be continued and expanded to understand and contain VAPI.

Ashley Yeager is an associate editor atThe Scientist. Email her atayeager@the-scientist.com. Follow her on Twitter@AshleyJYeager.

View original post here:
Vapers Reported Adverse Health Effects Online for Years: Study - The Scientist